H.Res. 787 · 115th Congress
Providing for consideration of the bill (H.R. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.R. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes; and for other purposes.
Agreed
See what this could mean for your district
Save your district in Account to view district-specific context for this bill.
Bill details
Introduced: 3/19/2018
Current status: Agreed
Introduced by: Michael Burgess (R · TX-26)
Bill ID: 115hres787
Latest official action: Motion to reconsider laid on the table Agreed to without objection.
Bill overview
No official congressional summary is available yet for this bill.
You can still review the official record or use the bill number to research it further.
Bill number: 115hres787
Related votes
Roll calls that reference this bill in official data.
0 roll calls
No related roll calls found yet for this bill.
Primary sources
Official links to verify details. No interpretation.
About this data
Non-partisan by design
OurCongress presents public records without political endorsement, interpretation, or advocacy.
Official sources
Data is sourced from official government records, including Congress.gov, GovInfo, the Clerk of the House, and the U.S. Senate.
AI-generated text
Some explanatory sections may be generated from official summaries and metadata to improve readability. They are not official government language and should be verified against primary sources.